Asosiy kontentga oʻtish
proceeding

HETEROCYCLIC HYBRID MOLECULES IN THE MULTITARGET SEARCH FOR PARKINSON’S DISEASE THERAPIES

Akhmadjonov K.K.Tashkent Pharmaceutical Institute, Tashkent, UzbekistanAzizbek Azamatov²S.Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uz-bekistan, Tashkent, UzbekistanU.A. Kurbonov²S.Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uz-bekistan, Tashkent, UzbekistanZhurakulov Sh.N.²S.Yu. Yunusov Institute of the Chemistry of Plant Substances, Academy of Sciences of the Republic of Uz-bekistan, Tashkent, Uzbekistan
2026
ABI

Annotatsiya

The complexity of Parkinson’s disease pathogenesis has stimulated the search for molecules capable of modulating several biologically related processes. In medicinal chemistry, one strategy is the design of multitarget-directed ligands that combine two or more pharmacophoric elements. Quinoline and isoquinoline moieties may serve as structural platforms for varying molecular geometry, electronic characteristics, and physicochemical profiles; however, these scaffolds alone do not determine a compound’s activity or safety. When designing a hybrid molecule, the selection of each putative target must be justified, and the rationale for simultaneous modulation of these targets must be explained. The way structural fragments are combined—through ring fusion or a linker—influences conformational flexibility, molecular weight, solubility, lipophilicity, and the number of rotatable bonds. Optimising affinity for one target must not lead to an unacceptable loss of blood–brain barrier permeability, metabolic stability, or tolerability [1]. Computational tools can support early-stage prioritisation: docking generates hypotheses about binding modes, molecular dynamics can be used to examine the stability of a predicted complex, and ADMET predictions help identify potential pharmacokinetic limitations. These methods do not replace direct measurement of biological activity. Confirmation of a multitarget profile requires independent biochemical assays, assessment of selectivity, and subsequent evaluation in cellular systems. Further validation should proceed in stages—from confirming target engagement and assessing cytotoxicity to examining cellular mechanisms, central nervous system exposure, and tolerability, followed by testing in appropriately selected in vivo models. If a neuroprotective mechanism is proposed, behavioural measures alone are insufficient; independent markers of the relevant pathological process are required. This design helps distinguish a structural hypothesis from a pharmacological property that has been experimentally demonstrated. Thus, the promise of heterocyclic hybrids should be evaluated not by the mere combination of pharmacophores but by the completeness and consistency of evidence at each stage. Rational design requires biologically justified target selection, controlled optimisation of molecular properties, experimental validation of computational predictions, and transparent criteria for progressing from a chemical candidate to preclinical investigation.

Hali tarjima qilinmagan

Identifikatorlar

Iqtiboslar va manbalar